Date: 2014-06-26
Type of information: R&D agreement
Compound: Xpandomers™
Company: Roche (Switzerland) Stratos Genomics (USA - WA)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism:
Disease:
Details: * On June 26, 2014, Roche announced it made a strategic investment in Stratos Genomics and entered into a research collaboration to support further development of their chemistry applied to single molecule sequencing of DNA fragments using protein nanopores. During this collaboration, a focused research team at Roche will work with Stratos scientists to support the development of efficient, low-cost sample preparation methods for DNA Xpandomers™ and also improve sequencing performance, by leveraging Roche’s expertise in protein design, polymerase mutagenesis, modified nucleotide chemistries and rare reagent manufacturing.
Stratos Genomics has pioneered a “Sequencing By Expansion™” (SBX™) method, which is a single molecule detection process that converts DNA into a larger surrogate molecule, called an Xpandomer™. These Xpandomer™ molecules, 10-100 times longer than the original DNA, pass through a nanopore which has a detector to read out the signal. A polymerase can be used to synthesize the Xpandomers™ from a DNA template by incorporating customized expandable nucleotides and increasing the surrogate molecule through a rapid chemical reaction. SBX’s signal to noise advantage has the potential to enable accurate, high throughput sequencing on reduced cost nanopore systems.
Financial terms:
Latest news:
